Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amarin Corporation plc - American Depositary Shares (NQ: AMRN ) 0.4487 -0.0080 (-1.75%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Amarin Corporation plc - American Depositary Shares < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Amarin Receives National Reimbursement for VAZKEPA® in Italy December 16, 2024 From Amarin Corporation plc Via GlobeNewswire Amarin Appoints Peter Fishman Chief Financial Officer December 13, 2024 Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company From Amarin Corporation plc Via GlobeNewswire Top 3 Health Care Stocks You'll Regret Missing In Q4 November 19, 2024 Via Benzinga Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual November 11, 2024 From Amarin Corporation plc Via GlobeNewswire Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript October 31, 2024 AMRN earnings call for the period ending September 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update October 30, 2024 From Amarin Corporation plc Via GlobeNewswire Amarin Announces Two Upcoming Investor Events October 01, 2024 From Amarin Corporation plc Via GlobeNewswire Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual September 09, 2024 From Amarin Corporation plc Via GlobeNewswire Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress August 22, 2024 From Amarin Corporation plc Via GlobeNewswire Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript July 31, 2024 AMRN earnings call for the period ending June 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update July 31, 2024 From Amarin Corporation plc Via GlobeNewswire 3 Breakthrough Stocks Under $10 Set for Massive Upside July 29, 2024 Discover the top breakthrough stocks under $10 with strong fundamentals and strategic advantages to hit massive upside. Via InvestorPlace Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal July 17, 2024 From Amarin Corporation plc Via GlobeNewswire Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 July 17, 2024 From Amarin Corporation plc Via GlobeNewswire Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) July 08, 2024 From Amarin Corporation plc Via GlobeNewswire What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients July 05, 2024 A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. Via Investor's Business Daily Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session June 04, 2024 Via Benzinga Amarin Board of Directors Announces CEO Transition June 04, 2024 From Amarin Corporation plc Via GlobeNewswire Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. May 28, 2024 From Amarin Corporation plc Via GlobeNewswire Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference May 06, 2024 From Amarin Corporation plc Via GlobeNewswire AMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024 May 01, 2024 AMRN stock results show that Amarin Corp beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript May 01, 2024 AMRN earnings call for the period ending March 31, 2024. Via The Motley Fool Topics Earnings Exposures Financial Amarin Reports First Quarter 2024 Business Update and Financial Results May 01, 2024 From Amarin Corporation plc Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session April 24, 2024 Via Benzinga Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event April 24, 2024 Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients From Amarin Corporation plc Via GlobeNewswire Amarin Announces Results of Annual General Meeting of Shareholders April 22, 2024 - Shareholders Approve Share Repurchase Program of up to $50 Million - From Amarin Corporation plc Via GlobeNewswire Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 April 15, 2024 From Amarin Corporation plc Via GlobeNewswire Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 April 08, 2024 Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action From Amarin Corporation plc Via GlobeNewswire New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups April 06, 2024 From Amarin Corporation plc Via GlobeNewswire Why Amarin Stock Was Rocketing Higher on Wednesday April 03, 2024 There was unambigously good news about the company's single commercialized medication. Via The Motley Fool < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
